BSE filing, BSE: 543943. Summary written from the filing by ALFA Finder's alert engine.
Asarfi Hospital Ltd: key numbers
- Share price
- ₹159.05
- Market cap
- ₹313.0 Cr
- Revenue (annual)
- ₹173.5 Cr
- Net profit (annual)
- ₹16.66 Cr
- P/E (TTM)
- 18.8×Sector 33.8×
- Promoter holding
- 61.18%+0.01% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asarfi Hospital Ltd
All →Asarfi Hospital Other Announcement
Asarfi Hospital Ltd has filed its shareholding pattern for the quarter ended September 30, 2026. This disclosure outlines the current distribution of equity shares.
Asarfi Hospital Credit Rating
Asarfi Hospital Ltd announced that CRISIL Ratings upgraded its bank facilities credit rating. The total rated bank facilities are now ₹60 Crore, enhanced from ₹46.5 Crore.
- Value
- ₹60.00 Cr
Asarfi Hospital Annual General Meeting
Asarfi Hospital Ltd's 21st Annual General Meeting held on September 18, 2026, saw shareholder approval for financial statements, director reappointment, and migration to the BSE Main Board.
Asarfi Hospital Annual Report
Asarfi Hospital Limited has submitted its Annual Report for the Financial Year 2025-26 in compliance with SEBI Listing Regulations.
Asarfi Hospital Other Announcement
Asarfi Hospital Limited has appointed M/s Ashutosh Kumar Sinha & Co as the Cost Auditor for the financial year 2026-27, as approved by the Board.
Asarfi Hospital Board Meeting Outcome
Asarfi Hospital approved its 21st AGM, appointment of auditors, and migration from BSE SME to the BSE Main Board and NSE.
Other board meeting date announcements
All →Premier Synthetics Board Meeting Date
Premier Synthetics announced its Board of Directors meeting scheduled for 14 November 2026 to consider unaudited Q2 and H1 results. No financial figures or decisions are reported in this advance notice.
HCP Plastene Bulkpack Board Meeting Date
HCP Plastene Bulkpack scheduled a board meeting for 06 November 2026. It will consider unaudited results for the quarter and half year ending 30 September 2026.
Ultracab (India) Board Meeting Date
Ultracab (India) Ltd intimated that its Board meeting is scheduled for 04-Nov-2026 to consider unaudited standalone financial results. No results or financial figures are disclosed in this advance notice.
Texmaco Infrastructure & Holdings Board Meeting Date
Texmaco has scheduled a Board meeting on November 5, 2026, to approve Q2 and H2 FY27 financial results. Trading window stays closed for insiders pending results declaration.
Astonea Labs Board Meeting Date
Astonea Labs intimated that its Board is scheduled on 14 Nov 2026 to consider unaudited half-year results. The trading window remains closed until 48 hours post-announcement.
AstraZeneca Pharma India Board Meeting Date
AstraZeneca Pharma India scheduled its board meeting for 5 Nov 2026 to approve Q2/H1 FY27 results. The trading window remains closed until 7 Nov 2026.